

Date of Deposit: November 4, 1999

PATENTAttorney's Ref. No. 245-53722

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box PATENT APPLICATION
 ASSISTANT COMMISSIONER FOR PATENTS
 Washington, D.C. 20231

Transmitted herewith for filing is the patent application of:

Inventor(s): Walt Ream, Machteld Mok, and Hyewon Lee

For: PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND
 COMPOSITIONS FOR PRODUCING SAME

Enclosed are:

- ☒ 31 pages of specification, 4 pages of claims, an abstract and a
 Combined Declaration and Power of Attorney.
- ☒ 5 sheet(s) of informal drawings.
- ☒ Verified Statement(s) (Declaration) Claiming Small Entity Status:
- ☐ Independent Inventor (37 CFR §§ 1.9(f) and 1.27(b)).
- ☒ Small Business Concern (37 CFR §§ 1.9(f) and 1.27(c)).
- ☐ Nonprofit Organization (37 CFR §§ 1.9(f) and 1.27(d)).
- ☐ Non-Inventor Supporting a Claim by Another for Small Entity Status
 (37 CFR §§ 1.9(c) and 1.27(b)).
- ☒ Nucleotide and/or Amino Acid Sequence Submission
- ☒ Electronic Format, on computer disk
- ☒ Paper Copy (identical to computer copy), 5 pages
- ☒ Statement in compliance with 37 C.F.R. § 1.821 verifying identity of
 above copies

FILING FEE					
For	Claims Filed	Number Free	Number Extra	Rate	Basic Fee \$760.00
Total Claims	28	20	= 8	\$18.00	\$ 144.00
Independent Claims	5	3	= 2	\$78.00	\$ 156.00
Multiple Dependent Claim Fee				\$260.00	
TOTAL FILING FEE					\$1060.00

- ☒ A check in the amount of \$1,060.00 to cover ☒ filing fee and ☐
 assignment recordal fee is enclosed.

Date of Deposit: November 4, 1999


PATENT

Attorney's Ref. No. 245-53722

- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By 
Paula A. DeGrandis
Registration No. 43,581

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Client
Docketing Secretary

PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND COMPOSITIONS FOR PRODUCING SAME

CROSS REFERENCE TO RELATED CASES

5 This application claims priority from a co-pending U.S. Provisional Application No. 60/107,185, filed November 5, 1998, which is incorporated herein by reference.

FIELD OF THE INVENTION

10 This invention is directed generally to compositions and methods for producing plants resistant to gall disease. The methods involve transforming plants with nucleic acid constructs encoding sense-strand untranslatable RNA molecules and/or double-stranded RNA molecules, RNA molecules that are similar to (but not identical to) certain *Agrobacterium* tumor-inducing genes.

15

BACKGROUND OF THE INVENTION

Several different recombinant DNA technologies have been employed to interfere with gene expression in plants including technologies based on ribozyme molecules, antisense RNA molecules, and co-suppression constructs. For a general
20 discussion of ribozyme technology, antisense technology and co-suppression technology, see Castanotto, *Crit. Rev. Eukaryot. Gen. Expr.* **2**:331-357, 1997; Simons, *Gene*, **72**:35-44, 1988; and Jorgensen, *Biotechnol.* **8**:340-344, 1990, respectively.

In addition to standard co-suppression techniques, researchers have studied
25 the suppression of a target gene caused by the introduction of an untranslatable sense-strand transgene. (Dougherty and Parks, *Curr. Opin. Cell Biol.* **7**:399-405, 1995; Jorgensen et al., *Science*, **279**:1486-1487, 1998). This method has been used to silence a number of endogenous plant genes, as well as viral genes. (Marano and Baulcombe, *Plant J.* **13**:537-546, 1998; Conner et al., *Plant J.* **11**:809-823, 1997,
30 Dougherty et al., *Mol. Plant-Microbe Interact.* **7**:544-552, 1994; and Smith et al., *Plant Cell* **6**:1441-1453, 1994).

The bacterial genus *Agrobacterium* contains several species that cause disease in economically important plants. For example, *Agrobacterium tumefaciens* causes gall tumors when it infects the wounded tissue of certain dicotyledonous plants such as apple trees and grape vines (DeCleene and DeLey, *Bot. Rev.* **42**:389-466, 1976). Pathogenic strains of *Agrobacterium* harbor a tumor-inducing (Ti) plasmid that carries genes essential for gall tumorigenesis (Watson et al., *J. Bacteriol.* **123**:255-264, 1975; Van Larebeke et al., *Nature* **252**:169-170, 1974). The transferred DNA ("T-DNA"; **Figure 1**) portion of the Ti plasmid enters the cells of susceptible plants and integrates into nuclear DNA (Chilton et al., *Cell* **11**:263-271, 1977; Willmitzer et al., *Nature* **287**:359-361, 1980; Chilton et al., *Proc. Natl. Acad. Sci. USA* **77**:4060-4064, 1980). Following T-DNA integration in cellular DNA, expression of three T-DNA genes, *iaaM*, *iaaH*, and *ipt*, leads to overproduction of the plant growth hormones auxin and cytokinin, resulting in tumorous growths referred to as "galls." (Ream, *Annual Rev. Phytopathol.* **27**:583-618, 1989; Winans, *Micro. Revs.* **56**:12-31, 1992; and Zambryski, *Annu. Rev. Plant Physiol. Plant Mol. Biol.* **43**:465-490, 1992) (**Figure 2**). The *iaaM*, *iaaH*, and *ipt* genes have been well characterized, and the sequences of these genes are available for example in the Genbank database under accession numbers X56185, M25805, and X17428, respectively.

iaaM and *iaaH* are required for auxin production: the enzyme encoded by *iaaM* converts tryptophan into indole acetamide, which the enzyme encoded by *iaaH* converts into indole acetic acid, an auxin (Schroeder et al., *Eur. J. Biochem.* **138**:387-391, 1984; Thomashow et al., *Proc. Natl Acad. Sci.* **81**:5071-5075, 1985; Thomashow et al., *Science* **231**:616-618, 1986; and Inze et al., *Mol. Gen. Genet.* **194**:265-274, 1984). Loss of either enzyme prevents auxin production. *ipt* is required for cytokinin production; the enzyme encoded by this gene converts adenosine monophosphate into isopentenyl adenosine monophosphate, a cytokinin (Akiyoshi et al. *Proc. Natl. Acad. Sci. USA* **81**:5994-5998, 1984; Barry et al., *Proc. Natl. Acad. Sci. USA* **81**:4776-4780, 1984; and Buchmann et al., *EMBO J.* **4**:853-859, 1985). Inactivation of *ipt* and either one of the two auxin-biosynthesis genes on

the Ti plasmid will reduce gall formation (Ream et al., *Proc. Natl. Acad. Sci. USA* **80**:1660-1664, 1983).

Additionally, galls can be formed in cases in which just the cytokinin pathway, or only the auxin biosynthesis pathway, is functional. In these cases the galls are visually distinguishable based on their different morphological characteristics. For example, plants infected with an *Agrobacterium* strain that carries only the gene necessary for the production of auxin develop necrotic galls. In contrast, plants infected with strains of the bacteria that induce only the production of cytokinin produce shooty galls.

To date, adequate means do not exist to control gall disease on grape vines, fruit trees, nut trees, chrysanthemums, roses, cane berries, ornamental shrubs, and other nursery crops. Inoculation of plants with *Agrobacterium radiobacter* strain K84 affords some protection against specific strains of *A. tumefaciens* (Moore, *Microbiol. Sci.* **5**:92-95, 1988); however, gall disease remains a multimillion dollar worldwide problem. *Arabidopsis thaliana* plants resistant to gall disease have been produced by a traditional genetic approach (Nam et al., *Plant Cell* **9**:317-333, 1997), but this strategy currently is not applicable to plants in which gall is a problem.

This invention is directed towards a new, more effective method of producing plants that are substantially resistant to gall disease caused by bacteria.

SUMMARY OF THE INVENTION

The present invention provides compositions that can be used to prevent tumor (gall) formation in plants infected with bacterial pathogens such as *Agrobacterium tumefaciens* and other species of *Agrobacterium*. These compositions comprise nucleic acid molecules that, when introduced into plants, can produce transgenic plants having enhanced resistance to tumors caused by such pathogens. The invention also encompasses transgenic plants that contain these nucleic acid molecules.

In general terms, the invention involves the use of nucleic acid constructs that encode untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules that share specified high levels of sequence identity with target genes in the bacterial pathogen. For example, the constructs may encode one or more types of untranslatable RNA molecules sharing high levels of sequence identity with one or more of the *iaaM*, *iaaH*, or *ipt* tumor genes of *Agrobacterium*. The invention also provides nucleic acid constructs that encode multiple different untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules, including both sense and antisense RNA molecules. For example, one construct provided by the invention encodes untranslatable RNA forms of both the *ipt* and *iaaM* genes of *Agrobacterium tumefaciens*; this construct can suppress both shooty and necrotic gall formation in plants caused by a pathogenic strain of *A. tumefaciens* infecting the plant.

The untranslatable RNA molecules appear to inhibit gall formation by triggering sequence-specific destruction of RNA molecules encoded by certain "target genes" of the infecting pathogen in the plant. However, the mechanism by which this occurs is not fully understood. For optimal efficacy, the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules should be of a sufficient length and share a minimum degree of sequence identity with the target bacterial gene such that disease resistance is conferred to the host cell. The level of disease resistance conferred to the host cell by the RNA molecule can be determined using the experiments described below. Thus, the RNA molecules encoded by the constructs provided herein are typically at least 25 nucleotides in length and share at least 60% sequence identity with the target gene of the pathogen. However, enhanced tumor suppression may be obtained by increasing the length of the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules (e.g., to at least 100, or at least 200 nucleotides) and/or by enhancing the level of sequence identity with the target gene (e.g., to at least 70%, 75%, 80%, or 90% sequence identity).

The invention also provides transgenic plants containing one or more of the above-described nucleic acid constructs. These constructs may be introduced into any plant species, but commercial crop plants for which *Agrobacterium* is a significant pathogen are expected to be particularly benefited by this technology.

The invention also provides chimeric plants that include both untransformed cells and transformed cells. These plants display "conferred resistance" in that the transgenic portion confers disease resistance to the non-transgenic portion. The chimeric plants are particularly useful for generating resistant, but not transgenic, fruits and other consumable portions of plants that are not transgenic.

SEQUENCE LISTINGS

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three-letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

SEQ ID NO: 1 is a primer used to produce the mutant *iaaM* gene.

SEQ ID NO: 2 is a primer used to produce the mutant *iaaM* gene.

SEQ ID NO: 3 is a primer used to produce the mutant *ipt* gene.

SEQ ID NO: 4 is a primer used to produce the mutant *ipt* gene.

SEQ ID NO: 5 is the DNA sequence that encodes an untranslatable RNA molecule having a high sequence identity with the *Agrobacterium ipt* gene.

SEQ ID NO: 6 is an amino acid sequence that is encoded by the untranslatable RNA molecule depicted in SEQ ID NO: 5.

SEQ ID NO: 7 is a DNA sequence encoding the untranslatable RNA molecule having a high sequence identity with the *Agrobacterium iaaM* gene.

SEQ ID NO: 8 is an amino acid sequence encoded by the untranslatable RNA molecule depicted in SEQ ID NO: 7.

SEQ ID NO: 9 is the nucleic acid sequence of the *ipt/iaaM* untranslatable construct.

SEQ ID NO: 10 is the nucleic acid sequence of the *iaaM* gene.

SEQ ID NO: 11 is the nucleic acid sequence of the *iaaH* gene.

SEQ ID NO: 12 is the nucleic acid sequence of the *ipt* gene.

5

DESCRIPTION OF DRAWINGS

Figure 1 is a diagram of the *A. tumefaciens* transferred DNA ("T-DNA") that contains three oncogenes: *iaaM*, *iaaH*, and *ipt*. Triangles represent T-DNA border sequences which delimit T-DNA ends by initiating and terminating T-DNA transfer (Peralta and Ream *Proc. Natl. Acad. Sci.* **82**:5112-5116, 1985). Arrows show direction and length of messenger RNAs (mRNAs) produced in gall tumors.

10

Figure 2 is a diagram of the auxin and cytokinin biosynthetic pathways encoded by the *A. tumefaciens* T-DNA oncogenes.

Figure 3 is a diagram of the binary plant transformation vector (pPEV6) (panel A) and of mutant transgenes that can be used to elicit co-suppression of T-DNA oncogenes. "RB" and "LB" denote right and left T-DNA border sequences, respectively. NOS prom/NPTII denotes the nopaline synthase promoter fused to the neomycin phosphotransferase II gene (conferring kanamycin resistance). 5' UTR and 3' UTR denote the 5' and 3' untranslated regions, respectively, associated with the cauliflower mosaic virus promoter (CaMV 35S Pro). Arrowheads denote respective restriction sites for *Xba*I, *Bam*HI, and *Eco*RI; numbers indicate respective coordinates relative to the vector sequence. Premature stop codons are shown in bold, whereas natural start codons are shown in plain text.

15

20

25

Figure 4 illustrates the most likely scenario for the creation of double-stranded RNA. The sense strand is transcribed from the CaMV 35S promoter and the anti-sense strand is transcribed from the NOS promoter.

Figures 5(A)-5(F) depict several representative illustrations of bacterial-resistance constructs (BR construct) according to the invention. Promoters are designated by the capital letter "P" and the direction of expression is denoted by respective arrows. DNA sequences encoding untranslatable RNA molecules that target specific genes are indicated; however, one of ordinary skill in the relevant art

30

66407-245-53722

will appreciate that untranslatable RNA molecules targeting other genes can be substituted. **Figure 5(A)** shows a BR construct in which one promoter (designated P_1) is used to express (direction of expression is indicated by the arrows) a DNA sequence encoding the sense-strand of a sequence that targets the *ipt* gene and the sense-strand of a sequence targeting the *iaaM* gene. This same construct also contains a second promoter (designated P_2) that drives the expression of the antisense-strand of the *iaaM* gene and the antisense-strand of the *ipt* gene. Thus, the combination of both promoters will generate a double-stranded RNA that contains a section targeting the *ipt* gene and a section targeting the *iaaM* gene. **Figure 5(B)** shows a BR construct that contains one promoter (P_1) that expresses a DNA sequence encoding several different untranslatable RNA sequences that target both the *ipt* gene and the *iaaM* gene. Starting at the 5' end of the construct, the promoter P_1 drives the expression of a sense-strand targeting the *ipt* gene, a sense-strand targeting the *iaaM* gene, an antisense-strand targeting the *iaaM* gene, and a sense-strand targeting the *ipt* gene. This sequence can fold back on itself, and thus generate a double-stranded RNA molecule comprising regions homologous to both the *ipt* and *iaaM* gene. **Figure 5(C)** shows another variation of a BR construct. This construct comprises independent promoters, P_1 and P_2 , to drive the expression of an untranslatable RNA molecule in both the sense and anti-sense orientations, respectively. Two additional promoters (P_3 and P_4) are utilized for the expression of the sense and anti-sense expression of a second untranslatable RNA. **Figure 5(D)** shows another variation of the BR construct. This construct comprises one promoter (P_1) to express first the sense-strand and then the antisense-strand of an untranslatable RNA molecule targeting the *ipt* gene. This construct also comprises a second promoter to express both the sense-strand and antisense-strand of an untranslatable RNA targeting the *iaaM* gene. **Figures 5(E) and 5(F)** illustrate additional variations that can be used to express single-stranded untranslatable RNA molecules.

DETAILED DESCRIPTION

I. Definitions and Abbreviations:

Untranslatable RNA molecule: An RNA molecule, either single-stranded or double-stranded, that is based on a naturally occurring RNA molecule but which, as a result of genetic manipulation, is incapable of being translated to yield the full-length protein encoded by its naturally occurring counterpart. For example, such RNA can be rendered untranslatable through the introduction of one or more premature termination codons (TAA, TAG, or TGA), or by introduction of a mutation that shifts the reading frame. Alternatively, for example, the RNA may be rendered untranslatable by the deletion of the AUG translation-initiation codon, or of the AAUAAA polyadenylation signal. The RNA may also be rendered untranslatable by simply removing a portion of the cDNA encoding the full-length protein. Thus, even if the sequence were translated, it would produce a truncated version of its naturally occurring counterpart.

Antisense-strand RNA: An RNA molecule that is complementary to a messenger RNA (which represents a corresponding “sense” strand).

Disease-resistant transgenic plant: A “disease-resistant transgenic plant” as used herein is a transgenic plant exhibiting more resistance to gall disease than a corresponding non-transgenic plant.

Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence whenever the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous.

Recombinant: A recombinant nucleic acid is one having a sequence that is not naturally occurring in the organism in which it is expressed, or has a sequence made by an artificial combination of two otherwise-separated, shorter sequences. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g.,

by genetic engineering techniques. "Recombinant" is also used to describe nucleic acid molecules that have been artificially manipulated, but that contain the same control sequences and coding regions that are found in the organism from which the gene was isolated.

5 **Sense-strand RNA:** An RNA molecule that can serve directly as messenger RNA, i.e., that can be translated by ribosomes.

Double-stranded RNA: A "double-stranded RNA" is an RNA molecule that contains at least a 25-bp sequence including both a sense-strand and an antisense-strand. Double-stranded RNA molecules are additionally characterized by
10 the level of complementarity between the sense-strand and the antisense-strand. Complementarity refers to the amount of base pairing between the two sequences. For example, the sequence 5'-AUCGGAUAGU-3' is 100% complementary to the sequence 5'-ACUAUCCGAU-3' and 70% complementary to the sequence 5'-GAAAUCCGAU-3'. The double-stranded RNA should be of a sufficient length and
15 have a sufficient level of complementarity such that it confers disease resistance to the host cell (disease resistance can be determined using the assays described below). For example, the double-stranded RNA may have as little as 60% complementarity. Generally, however, double-stranded RNA sequences will have at least 70%, 75%, 80%, or 90% complementarity.

20 **Vector:** A "vector" is a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences, such as an origin of replication, that permit the vector to replicate in a host cell. A vector may also include one or more screenable markers, selectable markers, or reporter genes and other genetic elements known in the art.

25 **Sequence identity:** The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences.

Methods for aligning sequences for comparison purposes are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, *Adv. Appl. Math.* **2**:482, 1981; Needleman & Wunsch, *J. Mol. Biol.* **48**:443, 1970; Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* **85**:2444-2448, 1988; Higgins and Sharp, *Gene* **73**:237-244, 1988; Higgins and Sharp, *CABIOS* **5**:151-153, 1989; Corpet et al., *Nucleic Acids Research* **16**:10881-10890, 1988; Huang, et al., *Computer Applications in the Biosciences* **8**:155-165, 1992; and Pearson et al., *Methods in Molecular Biology* **24**:307-331, 1994. Altschul et al., *J. Mol. Biol.*, **215**:403-410, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST™, Altschul et al., *J. Mol. Biol.*, **215**:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence-analysis programs blastp, blastn, blastx, tblastn and tblastx. BLAST™ can be accessed at <http://www.ncbi.nlm.nih.gov/BLAST/>. A description of how to determine sequence identity using this program is available at http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html.

For comparisons of amino acid sequences of greater than about 30 amino acids, the "Blast 2 sequences" function in the BLAST™ program is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per-residue gap cost of 1). When aligning short peptides (fewer than about 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins having even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity.

A first nucleic acid is "substantially similar" to a second nucleic acid if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other

nucleic acid (or its complementary strand), nucleotide sequence identity occurs in at least about 60%, 75%, 80%, 85%, 90% or 95% of the nucleotide bases (As used herein, "optimally aligned" sequences exhibit a maximal possible sequence identity). Sequence similarity can be determined by comparing the nucleotide sequences of

5 two nucleic acids using the BLAST™ sequence analysis software (blastn) available from The National Center for Biotechnology Information. Such comparisons may be made using the software set to default settings (expect = 10, filter = default, descriptions = 500 pairwise, alignments = 500, alignment view = standard, gap existence cost = 11, per residue existence = 1, per residue gap cost = 0.85).

- 10 Similarly, a first polypeptide is substantially similar to a second polypeptide if it shows sequence identity of at least about 75%-90% or greater when optimally aligned and compared using BLAST™ software (blastp) using default settings.

Bacterial resistance construct (BR construct): A "bacterial resistance construct" (abbreviated "BR construct") is a sequence of DNA that incorporates at

15 least one promoter and at least one DNA sequence encoding an untranslatable RNA (either double-stranded RNA, single-stranded RNA or a combination thereof). The arrangement of the promoter(s) in relationship to the DNA sequence(s) can vary. Representative configurations are illustrated in **Figures 5(A)-5(G)**. **Figure 5(A)** shows a BR construct in which one promoter (designated P₁) is used to express

20 (direction of expression is indicated by the arrows) a DNA sequence encoding the sense-strand of a sequence that targets the *ipt* gene and the sense-strand of a sequence targeting the *iaaM* gene. This same construct also contains a second promoter (designated P₂) that drives the expression of the antisense-strand of the *iaaM* gene and the antisense-strand of the *ipt* gene. Thus, the combination of both

25 promoters will generate a double-stranded RNA that contains a section targeting the *ipt* gene and a section targeting the *iaaM* gene. **Figure 5(B)** shows a construct that contains one promoter (P₁) that expresses a DNA sequence that encodes several different untranslatable RNA sequences targeting both the *ipt* gene and the *iaaM* gene. Starting at the 5' end of the construct, the promoter P₁ drives the expression of

30 a sense-strand targeting the *ipt* gene, a sense-strand targeting the *iaaM* gene, an

antisense-strand targeting the *iaaM* gene, and a sense-strand targeting the *ipt* gene.

This sequence can fold back on itself, and thus generate a double-stranded RNA molecule comprising regions homologous to both the *ipt* and *iaaM* gene. **Figure**

5(C) shows another variation of a BR construct. This construct comprises

5 independent promoters, P₁ and P₂, to drive the expression of an untranslatable RNA molecule in both the sense and anti-sense orientations, respectively. Two additional promoters (P₃ and P₄) are utilized for the expression of the sense and anti-sense strands of a second untranslatable RNA. **Figure 5(D)** shows another variation of the BR construct. This construct comprises one promoter (P₁) to express first the sense-strand and then the antisense-strand of an untranslatable RNA molecule targeting the *ipt* gene. This construct also comprises a second promoter to express both the sense-strand and antisense-strand of an untranslatable RNA targeting the *iaaM* gene.

10 **Figures 5(E) and 5(F)** illustrate additional variations that can be used to express single-stranded untranslatable RNA molecules. **Figures 5(A)-(F)** are intended to illustrate a few of various different promoter/DNA sequence combinations that are possible. A person of ordinary skill in the art will appreciate that many additional combinations can be used in BR constructs according to the invention.

II. General Description

20 The present method provides new and effective methods for suppressing the expression of *Agrobacterium* oncogenes. In particular, this invention is directed at, *inter alia*, producing plants that are capable of substantially inhibiting the formation of bacterially induced galls. These plants are produced by selecting a target gene of *Agrobacterium* origin, designing a nucleic acid (typically DNA) BR construct

25 encoding untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules having a high sequence identity to the target gene, and introducing at least one of these BR constructs into a host cell.

a. Selection of the Target Gene

There are many species of *Agrobacterium*, for example *Agrobacterium tumefaciens*, *Agrobacterium vitis*, *Agrobacterium rubi*, and *Agrobacterium rhizogenes*. The nucleic acid sequences of the respective oncogenes contained within these species are highly conserved. Therefore, a BR construct designed to encode at least one RNA molecule having high sequence identity to one or more target tumor-inducing *Agrobacterium* genes will likely confer resistance to at least one (typically multiple) species of *Agrobacterium*.

b. Producing a Nucleic Acid Construct Encoding an Untranslatable RNA

Practicing the present invention requires the manipulation of a DNA sequence using molecular biological techniques to produce the desired nucleic acid construct. The DNA sequence can be manipulated using standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage intermediate or with the use of specific oligonucleotides in combination with PCR. Details of these techniques are provided in standard laboratory manuals such as Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989, and Ausubel et al., *Short Protocols in Molecular Biology*, 2nd ed., John Wiley and Sons, 1992.

Suppression of an oncogene using a method according to this invention is achieved by expressing, in a host cell, molecules of a BR construct having high sequence identity to the target gene(s). At least one molecule of the BR construct having substantial sequence identity to the target gene(s) is introduced into a host cell. The BR construct can be delivered into the host cell genome by delivering into the host a vector cell containing the BR construct.

Application of the present invention to construction of a BR construct desirably involves the selection of appropriate control sequences such as promoters,

enhancers, and 3'-untranslated regions. The choice of which type of control sequence(s) to use in a BR construct will depend upon the particular tissue in which the BR construct will be expressed and the particular sequence(s) of the target gene(s). The variety of plant that is selected for transformation will also affect the choice of the control sequence(s), the vector, and the transformation method.

Constructing a suitable BR construct involves the selection of a DNA sequence that will be used to target at least one specific bacterial gene. Generally, the DNA sequence will encode an untranslatable RNA having at least 70% sequence identity with the target bacterial gene(s) (i.e., the gene(s) that will be suppressed).

In producing the BR construct, a DNA molecule homologous to a target bacterial gene can be manipulated to render a single-stranded RNA or double-stranded RNA molecule encoded by the DNA molecule untranslatable. This can be done by, e.g., introducing any of various stop signals into the open reading frame of the DNA molecule to produce the BR construct. For example, the BR construct can be configured to contain one or more premature stop codons. A "stop codon" is a codon of the genetic code that signals ribosomes to terminate translation of a messenger RNA molecule. There are three stop codons in the genetic code: TAA, TAG, and TGA, as illustrated in Table 1 below.

TABLE 1
The Genetic Code

	First Position	Second position				Third Position
5	(5' end)	T	C	A	G	(3' end)
10	T	Phe	Ser	Tyr	Cys	T
		Phe	Ser	Tyr	Cys	C
		Leu	Ser	STOP (och)	STOP	A
		Leu	Ser	STOP (amb)	Trp	G
	C	Leu	Pro	His	Arg	T
		Leu	Pro	His	Arg	C
		Leu	Pro	Gln	Arg	A
		Leu	Pro	Gln	Arg	G
15	A	Ile	Thr	Asn	Ser	T
		Ile	Thr	Asn	Ser	C
		Ile	Thr	Lys	Arg	A
		Met	Thr	Lys	Arg	G
	G	Val	Ala	Asp	Gly	T
		Val	Ala	Asp	Gly	C
		Val	Ala	Glu	Gly	A
		Val (Met)	Ala	Glu	Gly	G
20						

25 In the context of the foregoing discussion, a “premature” stop codon is located at a position transcriptionally upstream of a naturally occurring stop codon. Generally, the premature stop codon is positioned within 100 nucleotides of the translation-start codon, and typically within 50 nucleotides of the translation-start codon.

One or more stop codons can be inserted into the DNA sequence to produce
30 the BR construct. Alternatively, the DNA sequence can be mutated to convert an

existing triplet codon (encoding an amino acid) of the sequence into a stop codon.

For example, the hypothetical DNA sequence:

... CTT AAC TGG TCC ...

would normally produce a corresponding RNA translated by ribosomes to produce the polypeptide:

... Leu Asn Trp Ser ...

The corresponding RNA can be rendered untranslatable by introducing a stop codon, such as TAA, into the DNA sequence. For example, the modified DNA sequence:

... CTT TAA AAC TGG TCC ...

encodes:

... Leu STOP

Alternatively, in the foregoing hypothetical DNA sequence, substitution of the ninth nucleotide (guanosine (G)) by adenosine (A) will result in the creation of a premature stop codon, rendering the corresponding RNA untranslatable, i.e., the following DNA sequence is produced:

... CTT AAC TGA TCC ...

which encodes:

... Leu Asn STOP

Alternatively, the addition or deletion of one or more bases into or from, respectively, the DNA sequence (except multiples of three bases) can be used to displace the reading frame of the DNA sequence which can render the corresponding RNA molecule untranslatable. For example, the introduction of a single nucleotide

(G) into the first codon of the foregoing hypothetical DNA sequence creates a new reading frame containing a premature stop codon:

... CTG TAA CTG GTC C ...

5 which encodes:

... Leu STOP

10 An alternative manner of rendering an RNA molecule untranslatable is to remove the translation-initiation codon (usually ATG) from the corresponding DNA sequence. However, this method may result in use by ribosomes of an ATG codon elsewhere in the DNA sequence to initiate translation. Removal of the initiation codon ATG is, therefore, desirably used in conjunction with inserting one or more

15 premature stop codons into a DNA sequence.

Another method of introducing a premature stop codon is by truncating the subject DNA sequence. This can be done, for example, by using a restriction enzyme to excise a portion of a target gene and then cloning only the excised portion of the gene into a vector. Transcription of the vector will produce a segment of

20 homologous RNA effective to produce a co-suppression phenomenon, but will not produce a fully processed protein. Currently, the mechanism by which co-suppression works is not known. However, the phenomenon has been previously described in detail (Lindbo and Dougherty, *Virology* **189**:725-733, 1992).

One or more of the above approaches may be used to render an RNA

25 molecule encoded by a BR construct untranslatable. It will be appreciated that a very large number of sequence changes can be made in a suitable manner, the precise nature of which may depend on the actual DNA sequence being manipulated, to render the sequence of the corresponding RNA untranslatable. In certain embodiments, more than one stop codon may be introduced into the DNA sequence.

30 For example, the resulting BR construct may contain a DNA sequence encoding untranslatable RNA that has been altered to contain at least one stop codon situated early in the open reading frame; the open reading frame is thus "truncated."

Many standard DNA mutagenesis techniques are available to modify DNA sequences in a manner as described above to produce the BR construct. The mutagenesis techniques include, for example, M13 primer mutagenesis. Details of such techniques are provided in Sambrook et al., Chapter 15, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989; and in Ausubel et al., Chapter 8, *Short Protocols in Molecular Biology*, 2nd ed., John Wiley and Sons, 1992.

According to another aspect of the invention, double-stranded RNA molecules are provided that are homologous to a target bacterial gene. Each strand of the double-stranded RNA can be produced from separate BR constructs, wherein a first BR construct encodes the antisense-strand and a second BR construct encodes the sense-strand. Upon transcription of the first and second BR constructs, the resulting sense-strand and corresponding antisense-strand form double-stranded RNA.

Alternatively, the sense-strand and antisense-strand can be produced from a single BR construct. The single BR construct can utilize two distinct promoters to initiate the expression of the antisense-strand and the sense-strand, or one promoter to drive expression of both strands. When a single promoter is utilized, both the sense-strand and the antisense-strand are normally produced as a single transcript, wherein the RNA sequence will fold back on itself to create a double-stranded RNA. Similarly, multiple combinations of promoters, antisense-strands, and sense-strands can be encoded on the same BR construct.

Double-stranded RNA can also be produced by transforming cells with a BR construct that encodes the sense-strand, a self-cleaving ribozyme, and the antisense-strand all on a single transcript. Upon transcription of such a BR construct, the sense-strand, the self-cleaving ribozyme, and the antisense-strand are produced. The self-cleaving ribozyme sequence folds back on the resulting transcript and splices the transcript between the sense- and antisense-strands, generating two independent complementary strands of RNA.

A proposed mechanism for suppressing a target bacterial gene by introducing into a host cell molecules of a BR construct having one or more sequences homologous to at least a portion of the target gene typically involves the activity of an inducible, cellular activity that degrades specific RNA sequences. This
5 mechanism requires that the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA encoded by the BR construct be recognizable by the RNA-specific cellular activity. To such end, the target DNA sequence and the DNA sequence of the BR construct desirably share a sequence identity.

10 In the Examples presented below, the DNA sequences of the respective BR constructs are derived directly from corresponding target bacterial nucleotide sequences. The sequences of the respective BR constructs differ from the corresponding target sequences primarily only by the presence (in the sequences of the BR constructs) of premature stop codons inserted by mutagenesis involving one
15 or more frame-shift mutations. Thus, in these examples, the BR constructs have over 90% sequence identity to the corresponding target DNA sequences. However, a BR construct needs only to have sufficient sequence identity to the target gene so that the BR construct confers disease resistance to the host cell. Therefore, a BR construct that encodes an RNA molecule having less than 90% sequence identity to
20 the corresponding target DNA sequence can be used. In any event, the BR construct typically has at least 60% sequence identity to the corresponding target DNA molecule, and in some cases at least 70%, 75%, or 80% sequence identity to the target DNA molecule.

25 The following examples also describe BR constructs in which the DNA sequence corresponds to 700 base pairs of the ORF (open reading frame) of the target gene. It will be understood, however, that the untranslatable RNA provided by the BR construct need not correspond specifically to 700 base pairs of the ORF of the target gene; substantially shorter sequences of untranslatable RNA may also be effective.

5 The BR construct should be sufficiently long and share a sufficient level of sequence identity to the target gene such that the BR construct confers disease resistance to the host cell. The ability of a particular BR construct to confer disease resistance to a host cell can readily be determined by using the assay described below, in which a transgenic plant is challenged with a bacterial pathogen. Typically, the ORF of the DNA sequence of the BR construct is at least 25-100 nucleotides in length, although longer sequences, such as 100-250, 250-500, or greater than 500 nucleotides may be used and may provide superior results. In embodiments where shorter sequences (i.e., less than 250 nucleotides) are utilized, 10 the respective BR constructs will likely share a high degree of sequence identity (e.g., at least 60% sequence identity) with the target gene sequence.

The present invention can be used to suppress the expression of a bacterial tumor gene in a plant cell. To such end, the plant cell is transformed with a BR construct having a high sequence identity to a target bacterial gene. The molecule of 15 the BR construct encodes one or more untranslatable single-stranded RNA and/or double-stranded RNA molecules. The BR construct can comprise a sequence of at least 25 nucleotides in length having at least 60% sequence identity to the target bacterial gene. Alternatively, the BR construct can comprise a sequence of at least 100 nucleotides in length having at least 60% sequence identity to the target 20 bacterial gene. Furthermore, the BR construct can comprise a nucleic acid sequence of at least 250 nucleotides in length having at least 60% sequence identity to the target bacterial gene.

The present invention is not limited to the suppression of a single target bacterial gene. Rather, it is possible to suppress, according to the invention, the 25 expression of multiple target genes using one or more BR constructs that comprise DNA sequences corresponding to several respective genes expressed in the target cell. This approach can be used to enhance resistance to a single bacterial strain or to produce resistance to multiple strains of bacteria in a single plant. As illustrated in the Examples below, the formation of a gall on a plant by a pathogenic bacterium 30 infecting the plant can be reduced or eliminated by the introduction into the cells of

the plant, a BR construct having a high sequence identity to at least one gene of the infecting bacterium. This approach allows the production of transgenic plants resistant to the bacterium.

5 **c. Vectors**

It will be appreciated that the efficacy of the present invention depends on transcription of the DNA sequence of the BR construct introduced into a host plant cell. Transcription of a DNA sequence into messenger RNA is preferably effected by including a promoter region at the 5' end of the DNA sequence of the BR
10 construct, together with regulatory sequences at the 3' end of the DNA sequence. Many promoter sequences and 3'-regulatory sequences have been identified and characterized in a wide range of viral, bacterial, fungal, plant, and animal genes. Therefore, the selection of suitable promoter and a suitable 3'-regulatory sequence is within the capability of a person of ordinary skill in the relevant art.

15 After choosing and incorporating the appropriate regulatory DNA sequence(s) into the BR construct, the BR construct is incorporated into a suitable vector for introduction into the host cell. The choice of regulatory sequences, as well as the choice of a suitable transformation vector will depend upon the type of host cell into which the BR construct is to be introduced and upon the desired
20 transformation method for the host cell. Vectors suitable for transforming plant cells (derived from either monocotyledonous or dicotyledonous plants) are described below. Transformation of both monocotyledonous and dicotyledonous plant cells is now routine and the selection of the most appropriate transformation technique will be determined by the skilled practitioner.

25 A number of promoters that are active in plant cells have been described in the literature. Promoters that are known to cause transcription of DNA in plant cells can be used to suppress gene expression in plants. Such promoters can be obtained from plant cells or from plant viruses and include, but are not limited to, the CaMV (cauliflower mosaic virus) 35S promoter. It is desirable that the chosen promoter be
30 capable of causing sufficient expression of the BR construct to produce sufficient

RNA to suppress expression of the target gene. The amount of RNA needed to suppress expression of a particular target gene may vary from one target gene to another, expression level of the particular target gene, and the plant type.

Accordingly, whereas the CaMV promoter is employed in the Examples presented below, it will be understood that this promoter may not be optimal for all embodiments of the present invention.

The vector can be configured to optimally exploit the promoter and termination sequences in the target gene itself. Used in this way, the target-gene promoter is not altered and the subsequent stop signals are introduced into the ORF of the target gene. Additionally, the termination signals of the target gene can be left intact. This configuration permits increasing the transcription of untranslatable RNA and/or double-stranded RNA whenever the factors necessary for transcription of the target gene are present.

The promoter(s) used in a BR construct according to the invention may be modified, if desired, to include additional regulatory sequence(s). Such additional regulatory sequences can confer, e.g., specificity to the respective promoter region. For example, the small subunit of the ribulose bis-phosphate carboxylase ("ss RUBISCO") gene is expressed in plant leaves but not in root tissues. A sequence motif that represses the expression of the ss RUBISCO gene in the absence of light (to create a promoter which is active in leaves but not in root tissue), has been identified. This and/or other regulatory sequences such as the HSP70 leader sequence from petunia, may be ligated to promoters such as the CaMV 35S, or figwort mosaic virus (FMV) promoter, to modify the expression patterns of a gene.

The 3'-nontranslated region (that functions as a polyadenylation site for RNA in plant cells) of a gene can also be used in the present invention. Such 3'-non-translated regions include, but are not limited to, the 3'-transcribed (but non-translated) region of the CaMV 35S gene, the pea-rbcS E9 3'-non-translated region, the NOS 3'-non-translated region, and one or more of the 3'-transcribed, non-translated (but non-translated) regions containing the polyadenylation signals of the

tumor-inducing (Ti) genes of *Agrobacterium*, such as the tumor morphology large (*tml*) gene.

d. Plant Species

5 Gall formation in plants can be induced by any of various organisms. For example, galls can be induced by bacteria from the genus *Agrobacterium*, and certain species of *Pseudomonas*, *Rhizobacter*, and *Rhodococcus*.

In the case of *Agrobacterium*, gall formation is caused by genes introduced into the plant cells on the Ti plasmid provided by an infecting bacterium.

10 There are a variety of naturally occurring Ti plasmids that can give rise to different types of galls. Galls are normally caused by *A. tumefaciens* which infects over 391 genera of plants including shrubs, fruit trees, nut trees, tuber-producing plants, conifers, grape vines, chrysanthemums, roses, cane berries, nursery crops, and commercially important plants (Bradbury, J.F. Guide to Pathogenic Bacteria. CAB
15 International, Slough, Britain, 1986). Hairy root is another type of gall induced by *A. rhizogenes*, that primarily affects the roots of apple trees. Finally, *Agrobacterium rubi* can infect both raspberries and black berries, and give rise to cane galls. (Agrios, *Plant Pathology*, Academic Press, 1997).

20 **e. Transformation**

A BR construct according to the present invention is introduced into a plant cell using a suitable vector and transformation method as described below. The resulting transformed cells can then be allowed to regenerate into whole plants. Any of various conventional methods employed for transforming plant cells to generate
25 transgenic plants, including stably transformed plants, can be used in this invention. The choice of method will typically vary with the type of plant to be transformed; persons skilled in the art will recognize the suitability of particular methods for given plant types. Suitable methods may include, but are not limited to: electroporation of plant protoplasts; liposome mediated transformation; polyethylene
30 glycol-mediated transformation; transformation using viruses; microinjection of

plant cells; microprojectile bombardment of plant cells and *Agrobacterium tumefaciens* (AT)-mediated transformation. The DNA sequences comprising the CaMV 35S promoter and CaMV 35S non-translated 3' region and the mutated cDNA encoding a untranslatable RNA can be combined in a single cloning vector.

- 5 This vector can be transformed subsequently into, e.g., cultured tobacco cells.

f. Conferred Resistance

The mechanism of co-suppression is unknown. However, transgenic tissue containing a co-suppression gene can be grafted onto a non-transgenic plant. The graft then confers resistance to the non-transgenic plant (Jorgensen et al., *Science*, 10 **279**:1486-87, 1998). Furthermore, this "conferred resistance" can be established by either grafting a scion (upper vegetative tissue) onto a transgenic stock (lower vegetative tissue), or by grafting a transgenic scion onto a non-transgenic stock. This conferred resistance can be transmitted through at least 30 cm of non-transgenic tissue.

15 It is possible that the phenomenon of conferred resistance may allow resistance to gall formation to be introduced into existing plants. Thus, a mature plant can be made resistant to gall formation by grafting transgenic tissue onto the plant. Furthermore, several grafts can be placed independently on the plant to produce resistance in the plant to several different bacterial pathogens.

20 A grafting protocol can be made more flexible by utilizing cross-species grafting. Thus, a graft from, e.g., almond (*Prunus amygdalus*) can be placed on stock from peach (*Prunus persica*). Such flexibility increases the range of plants for which a given transgenic tissue can be used. For example, after almond tissue containing the desired BR construct has been generated, the tissue can be used to confer resistance not only to other almond trees, but also to peach trees.

25 The use of conferred resistance also decreases the possibility that a transgene made according to the invention will be introduced into the environment. This is because the resistance is derived from the graft itself and the rest of the plant

66407 264460

remains free of the transgene. Therefore, the fruits and seeds of the plant can be left non-transgenic, so as not to transmit the gene.

By preventing a transgene from being systemically introduced into the plant, products for human consumption can be produced by the plant that are not transgenic.

III. EXAMPLES

a. Construction of BR Constructs Encoding Untranslatable RNA molecules

To produce a DNA construct capable of eliciting co-suppression, the *iaaM* and *ipt* oncogenes were modified by changing the third codon of each gene to a stop codon and introducing a frameshift mutation downstream of each respective introduced stop codon, thereby creating additional stop codons in the reading frame (**Figure 3**). The polymerase chain reaction (PCR) primer oligonucleotides used to create these mutations in the DNA construct are described in Table 2. The primers used to modify the *ipt* gene resulted in the deletion of the 5' C of the third codon and changed the 3' G of the third codon to an A. The *iaaM* modifications introduced the stop sequence TGA at the third codon and the two bases following the third codon were deleted. A second DNA construct was made that contained a hybrid transgene configured to elicit co-suppression of both *ipt* and *iaaM*. The second DNA construct was made by digesting a vector (containing the *ipt*-stop mutation) and a vector containing the *iaaM*-stop mutation with *Bam*H1. The fragment containing the *iaaM*-stop mutation was then ligated into the fragment containing the *ipt*-stop mutation, thereby yielding a BR construct containing the mutant *iaaM* gene inserted into the mutant *ipt* gene (**Figure 3**). The sequence of each DNA construct was verified, and the BR construct was inserted into a plant-transformation vector (pPEV6; Lindbo and Dougherty, *Mol. Plant-Microbe Interact.* **5**:144-153, 1992) oriented such that the sense-strand of each mutant was expressed from the cauliflower mosaic virus (CaMV 35S) promoter (**Figure 3**).

Table 2PCR Primers Used to Produce Mutant *iaaM* and *ipt* Genes

Primers		Sequence
5	<i>iaaM</i> stop	5' primer 5'-CGGGATCCATGTCATGAACCTCTCCTTGA TAAC-3' (SEQ ID NO: 1)
		3' primer 5'-CGGGATCCTGCGACTCATAGT-3' (SEQ ID NO: 2)
10		
	<i>ipt</i> stop	5' primer 5'-GAAGATCTGATCATGGACTGAATCTAAT TTTCGGTCC-3' (SEQ ID NO: 3)
15		
		3' primer 5'-GAAGATCTGATCACTAATACATTCCGAAC GG-3' (SEQ ID NO: 4)

**b. Construction of Double-Stranded RNA and Untranslatable
Double-Stranded RNA Vectors**

A vector encoding an *iaaM*-stop mutation (i.e., a DNA construct modified to incorporate a stop codon at the third codon, followed by a two base pair deletion) exhibited evidence of bacterial resistance. This resistance was derived from the production of double-stranded RNA by transcription of the vector (**Figure 4**). The sense-strand of the double-stranded RNA was transcribed from the CaMV 35S promoter and the antisense-strand was probably transcribed from the nopaline synthase promoter (NOS). Thus, this vector can produce a long double-stranded RNA that is approximately 2,000 bp long. Evidence of such a double-stranded RNA was found in northern blots that showed partially degraded antisense-strands ranging in size from 3.4 Kb to less than 0.24 Kb. As is depicted in Figure 4, the double-stranded RNA appeared to include an approximately 2,000 bp long region that was 100% homologous to the *iaaM* sequence. Therefore, bacterial resistance observed in *iaaM*-transgenic plants is probably attributable to the presence of the double-

stranded RNA. This resistance does not appear to have been due solely to the presence of the introduced stop codon.

Double-stranded RNA is capable of suppressing endogenous plant genes, as well as suppressing viral infection (Ruiz et al., *Plant Cell* **10**:937-946, 1998).

- 5 However, the suppression, via double-stranded RNA and/or untranslatable RNA, of disease symptoms caused by bacteria, such as *Agrobacterium*, has previously not been shown.

c. Production of Plants Homozygous for Untranslatable RNA Transgenes

- 10 Mutant *iaaM* (SEQ ID NO: 7), *ipt* (SEQ ID NO: 5), and *ipt/iaaM* genes (SEQ ID NO: 9) were introduced separately into haploid tobacco (*N. tabacum*, "Burley" and "Kentucky" cultivars). The chromosomes of kanamycin-resistant transformants of these plants were doubled to produce plants homozygous for each transgene. These plants were the subjects of initial tests, which were repeated on the
- 15 F1 progeny of self pollinations.

d. Gall-resistant Plant Phenotypes

- Putative *iaaM*-suppressing plants (designated "TDP1" lines) were challenged with *ipt*-mutant *A. tumefaciens* (strain 338; Garfinkel et al., *Cell* **27**:143-153, 1981).
- 20 Of 63 lines tested, 35 lines, including TDP1-B7 & TDP1-B17, suppressed the wild-type *iaaM* gene on *A. tumefaciens* T-DNA introduced into such plants, thereby preventing tumorous growth in the respective plants. When inoculated with wild-type *A. tumefaciens* (strain A348; Garfinkel et al., *Cell* **27**:143-153, 1981), each of the 35 lines produced "shooty" galls typical of cytokinin-driven tumors, such as
- 25 those induced on wild-type plants inoculated with *iaaM*-mutant *A. tumefaciens* (Ream et al., *Proc. Natl. Acad. Sci. USA* **80**:1660-1664, 1983; and Garfinkel et al., *Cell* **27**:143-153, 1981). Thus, the plants that produced shooty galls exhibited the phenotype expected of a transgenic plant capable of suppressing *iaaM*.

- Putative *ipt*-suppressing plants (designated "CW1" lines) were challenged
- 30 with *iaaM*-mutant *A. tumefaciens* (strain 328; Garfinkel et al., *Cell* **27**:143-153,

1981). Of 45 lines investigated, one (designated "CW1-K27") clearly suppressed the wild-type *ipt* gene on introduced *A. tumefaciens* T-DNA. Another 6 lines exhibited similar results in initial tests on the original transgenic plants, but these lines were lost before seeds were obtained. The *ipt*-suppressing plant (CW1-K27),
5 when inoculated with wild-type *A. tumefaciens*, produced small necrotic galls typical of auxin-driven tumors, such as those induced on wild-type plants inoculated with *ipt*-mutant *A. tumefaciens* (Ream et al., *Proc. Natl. Acad. Sci. USA* **80**:1660-1664, 1983; Garfinkel et al., *Cell* **27**:143-153, 1981). There were 30 lines tested (designated "CW4" lines) that contained the hybrid *ipt-iaaM* transgene. One line
10 (designated "CW4-B30") exhibited a significant reduction in tumorigenesis when inoculated with either wild-type, *iaaM*-mutant, or *ipt*-mutant *A. tumefaciens*. Although the CW4-B30 line exhibited markedly reduced gall size and absence of gall formation at some inoculation sites, gall tumorigenesis was not entirely absent. The controls were kanamycin-resistant plant lines (designated "PEV6" lines) that
15 contained the transformation vector T-DNA (from pPEV6) without a transgene located downstream of the CaMV 35S promoter. As expected, none of these lines exhibited any suppression of T-DNA oncogenes upon infection with *A. tumefaciens*.

e. Molecular Analysis of Transgenic Plants

20 To examine transgene copy number and structural integrity, Southern blot analyses were performed on representative plant lines of each type. Most lines contained several copies of the transgene, and all lines contained one or more intact copies (see Tables 3, 4, and 5, below). Some lines also contained rearranged copies of the transgene, which were identified by the presence of multiple bands in the
25 Southern blots.

TABLE 3
Southern Blot of Genomic DNA Digested with *Bam*H1

Transgenic Plant	1799-bp Transgene Fragment (+/-)*	Oncogene Suppression (+/-)*
CW4 B1 (ipt-stop/iaaM-stop)	+	-
CW4 B11 (ipt-stop/iaaM-stop)	+	-
CW4 B22 (ipt-stop/iaaM-stop)	+	-
CW4 B30 (ipt-stop/iaaM-stop)	+	+/-
TDP1 B7 (iaaM-stop)	+	+
TDP1 B17 (iaaM-stop)	+	+
TDP1 B27 (iaaM-stop)	+	+
TDP1 B31 (iaaM-stop)	+	-
PEV6 B2 (vector alone)	-	-
PEV6 B14 (vector alone)	-	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.		

5

TABLE 4
Southern Blot of Genomic DNA Digested with *Eco*R1

Transgenic Plant	Transgene Copy Number	Oncogene Suppression (+/-)*
TDP1 B7 (iaaM-stop)	3-4	+
CW4 B1 (ipt-stop/iaaM-stop)	2	-
CW4 B11 (ipt-stop/iaaM-stop)	2	-
CW4 B22 (ipt-stop/iaaM-stop)	2	-
CW4 B30 (ipt-stop/iaaM-stop)	4	+/-
TDP1 B17 (iaaM-stop)	2	+
TDP1 B27 (iaaM-stop)	1	+
TDP1 B31 (iaaM-stop)	4<	-
PEV6 B2 (vector alone)	0	-
PEV6 B14 (vector alone)	0	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.		

10

TABLE 5
Southern Blot of Genomic DNA Digested with
either *Hinf*I or *Eco*R1 Digested Genomic DNA

Transgenic Plant	Presence of Restriction Fragment (+/-)*	Restriction Enzyme	Suppression of Oncogenes (+/-)*
CW1 K27 (ipt-stop)	+	<i>Hinf</i> I	+
CW1 K27 (ipt-stop)	+	<i>Eco</i> R1	+
CW1 K52 (ipt-stop)	+	<i>Hinf</i> I	-
CW1 K52 (ipt-stop)	+	<i>Eco</i> R1	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.			

5

The foregoing results show that co-suppression drastically reduces accumulation of mRNA encoded by the eliciting transgene and mRNA encoded by other genes that contain sufficient (approximately 70% or more) sequence similarity (Marano and Baulcombe, *Plant J.* **13**:537-546, 1998). Hence, Northern blot analysis was used to measure mRNA accumulation (but not transcription rate). In all *iaaM*-suppressing lines that were examined, transgene mRNA was undetectable, as expected, using a strand-specific hybridization probe. However, full-length and degraded antisense RNA molecules that included the transgene sequences were detected using a double-stranded hybridization probe. These transcripts appear to have initiated from the vector's nopaline synthase promoter and continued through both the neomycin phosphotransferase gene (in the sense direction) and the *iaaM* transgene (in the antisense direction). In the successful *ipt*-suppressing line, a trace amount of transgene-encoded mRNA was detected. Another line that contained the *ipt* transgene accumulated a large amount of transgene mRNA, but this line failed to co-suppress an incoming *A. tumefaciens* T-DNA-borne *ipt* gene. Plants that contained the hybrid *ipt-iaaM* transgene accumulated varying quantities of transgene-encoded mRNA. As expected, most of these lines did not elicit any co-suppression and only one line elicited partial co-suppression.

20

664947 2346460

f. Discussion

By studying the ability of wild-type and *iaaM*- or *ipt*-mutant *A. tumefaciens* to induce tumors on various lines of transgenic plants, it has been shown that: 1) many lines suppressed an incoming T-DNA *iaaM* gene, 2) one line suppressed an incoming T-DNA *ipt* gene, and 3) one line partially suppressed both *ipt* and *iaaM* genes simultaneously.

By combining successful *iaaH*- or *iaaM*-suppressing transgenes with an *ipt*-suppressing transgene in a single plant line, a transgenic plant fully resistant to gall formation can be produced. This can be done through standard breeding techniques, in which a cross between lines homozygous for the individual genes is performed. The F2 generation will include plants homozygous for both transgenes; such plants are expected to substantially resistant to gall formation. This expectation is supported by data from a plant that contained the hybrid *ipt-iaaM* transgene. This plant nearly prevented gall formation, indicating that a single hybrid gene can elicit co-suppression against two target oncogenes.

The transgenes used in this study will likely elicit co-suppression against a broad variety of *Agrobacterium* species, as well as various strains of such species. This allows the production of plants (such as grape vines, fruit trees, nut trees, and chrysanthemums) that are resistant to gall formation. Other studies have established that approximately 70% sequence identity is required to elicit co-suppression (Marano and Baulcombe, *Plant J.* **13**:537-546, 1998). Fortunately, the target T-DNA oncogenes (*iaaM* and *ipt*) are highly conserved among diverse *A. tumefaciens* strains. Even limited-host-range grape-specific *A. vitis* strains have greater than 90% sequence identity with the octopine-type oncogenes used in our study (Otten and DeRuffray, *Mol. Gen. Genet.* **245**:493-505, 1994).

Having illustrated and described the principles of the invention in multiple embodiments and examples, it should be apparent to those skilled in the art that the invention can be modified in arrangement and detail without departing from such principles. Therefore, the invention encompasses all modifications coming within the spirit and scope of the following claims.

Claims:

1. A method of producing a plant cell that is resistant to gall disease, the
5 method comprising transforming a plant cell with at least one nucleic acid molecule
that is homologous to at least one gene responsible for causing gall disease, the
nucleic acid molecule encoding an RNA molecule selected from the group
consisting of untranslatable plus-sense RNA molecules, double-stranded RNA
molecules, and untranslatable double-stranded RNA molecules.
- 10 2. The method of claim 1, wherein the nucleic acid molecule contains at
least one sequence that is homologous to at least one gene selected from the group
consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and fragments
thereof.
- 15 3. A plant-transformation vector, comprising the nucleic acid molecule
of claim 2.
4. A plant cell transformed with the plant-transformation vector of claim
20 3.
5. A differentiated plant, comprising plant cells produced according to
the method of claim 1.
- 25 6. A method of producing a plant exhibiting a reduced susceptibility to
gall disease caused by *Agrobacterium*, comprising:
transforming at least one plant cell with at least one nucleic acid
molecule that is homologous to at least one gene responsible for causing gall
disease, or fragment thereof, the nucleic acid molecule encoding an RNA molecule
30 selected from the group consisting of untranslatable plus-sense RNA molecules,

554077 20230406

double-stranded RNA molecules, and untranslatable double-stranded RNA molecules;

growing plants from the transformed plant cells; and

selecting a plant that shows a reduced susceptibility to gall disease

5 caused by *Agrobacterium*.

7. A plant exhibiting a reduced susceptibility to disease caused by *Agrobacterium*, produced by the method of claim 6.

10 8. A chimeric plant, comprising at least one non-transformed plant cell grafted to the plant of claim 7.

9. A plant produced by sexual or asexual reproduction of the plant of claim 7.
15

10. A seed produced by selfing or outcrossing the plant of claim 7.

11. A recombinant nucleic acid molecule comprising a nucleic acid sequence having at least 60% sequence identity with a nucleic acid sequence
20 selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and fragments thereof, the recombinant nucleic acid molecule, when introduced into and expressed in a plant, reduces susceptibility of the plant to disease caused by *Agrobacterium*.

25 12. A vector, comprising the recombinant nucleic acid molecule of claim 11.

13. A transgenic plant cell transformed with the vector of claim 12.

14. A transgenic plant, comprising at least one transgenic cell
30 transformed with a recombinant nucleic acid molecule, as recited in claim 13.

664077-284460

15. The transgenic plant of claim 14, wherein the plant is selected from the group consisting of apricot, blackberry, pear, peach, plum, blueberry, cherry, kiwi, quince, raspberry, and rose.

5

16. A chimeric plant, comprising at least one transgenic plant cell as recited in claim 13.

17. A BR construct.

10

18. A composition, comprising the BR construct of claim 17.

19. An RNA transcribed from the BR construct of claim 17.

15

20. A vector, comprising the BR construct of claim 17.

21. A plant cell transformed with the vector of claim 20.

22. A plant, comprising at least one plant cell according to claim 21.

20

23. A method of producing a plant cell that is resistant to gall disease, the method comprising:

providing a BR construct;

introducing the BR construct into a plant cell; and

25

assessing the level of gall resistance exhibited by the plant cell.

24. A plant, comprising at least one plant cell produced according to the method of claim 23.

25. The transgenic plant of claim 14, wherein the plant is
chrysanthemum.

26. The transgenic plant of claim 14, wherein the plant is selected from
5 the group consisting of conifers and poplars.

27. The transgenic plant of claim 14, wherein the plant is an ornamental
shrub.

10 28. The transgenic plant of claim 14, wherein the plant is selected from
the group consisting of almond, apple, grape, and walnut.

544277 229460

**PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS
AND COMPOSITIONS FOR PRODUCING SAME**

5

ABSTRACT

Methods and compositions for suppressing gall formation in plant cells induced by *Agrobacterium* infection are disclosed. The methods involve introducing at least one DNA construct, encoding at least one untranslatable sense-strand RNA and/or double-stranded RNA, into a plant cell. Introduction of these molecules into the plant cell causes the plant cells to become resistant to gall formation.

10

65407 2E34E60




Figure 1





Figure 2

Figure 2.

A. T-DNA of pPEV6 vector




B. TRANSGENE CONSTRUCT

TRANSGENIC
PLANT LINE

iaaM stop



ipt stop



ipt stop/iaaM stop



Figure 3.

Figure 3




Figure 4




Figure 5

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND COMPOSITIONS FOR PRODUCING SAME, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application No. _____.

☐ was described and claimed in PCT International Application No. _____, filed on _____, and as amended under PCT Article 19 on _____ (if applicable).

☐ and was amended on _____ (if applicable).

☐ with amendments through _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)

Priority
Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
-------------------	--------------------	---------------------------------	---------------------------------	--------------------------------

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

60/107,185

11-05-98

Application Number

Filing Date

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)

(Filing Date)

(Status: patented,
Pending, abandoned)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from _____ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application, to file a corresponding international application, and to transact all business in the Patent and Trademark Office connected therewith:

Name	Reg. No.	Name	Reg. No.
BEAN, Gregory V.	36,448	MAURER, Gregory L.	43,781
BECKER, Mark L.	31,325	MEYER, Joel R.	37,677
CALDWELL, Lisa M.	41,653	NOONAN, William D.	30,878
CAMPBELL, James	19,978	PETERSEN, David P.	28,106
DeGRANDIS, Paula A.	43,581	POLLEY, Richard J.	28,107
GEORGE, Samuel E.	44,119	SCOTTI, Robert F.	39,830
GIRARD, Michael P.	38,467	SIEGEL, Susan Alpert	43,121
JAKUBEK, Joseph T.	34,190	SLATER, Stacey C.	36,011
JOHNSON, Michelle L.	36,352	STEPHENS JR., Donald L.	34,022
JONES, Michael D.	41,879	STUART, John W.	24,540
KLARQUIST, Kenneth S.	16,445	VANDENBERG, John D.	31,312
KLITZKE II, Ramon A.	30,188	WHINSTON, Arthur L.	19,155
HARDING, Tanya M.	42,630	WIGHT, Stephen A.	37,759
LEIGH, James S.	20,434	WINN, Garth A.	33,220

Address all telephone calls to Paula A. DeGrandis at telephone number (503) 226-7391.

Address all correspondence to:

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP
One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, OR 97204-2988

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or first Inventor: Walt Ream

Inventor's Signature _____

Date

Residence: Corvallis, Oregon

Citizenship: U.S.A.

Post Office Address: 6005 N.W. Vineyard Dr.
Corvallis OR 97330

Full Name of Second Joint Inventor, if any: Machteld Mok

Inventor's Signature _____

Date

Residence: Corvallis, Oregon

Citizenship: U.S.A.

Post Office Address: 3024 N.W. Garryanna Dr.
Corvallis OR 97330

Full Name of Third Joint Inventor, if any: Hyewon Lee

Inventor's Signature _____

Date

Residence: Pusan, Korea

Citizenship: South Korea

Post Office Address: 304-1002 Sunkyung 3 cha-APT
Guseo-2-Dong Gumjeong-Ku
Pusan, 609-312
KOREA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Ream et al.

Art Unit: unassigned

Application No. new

Filed: November 4, 1999


For: PLANTS HAVING ENHANCED GALL
RESISTANCE AND METHODS AND
COMPOSITIONS FOR PRODUCING
SAME

Examiner: unassigned

Date: November 4, 1999

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 4, 1999 as First Class Mail in an envelope addressed to: BOX PATENT APPLICATION, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.



Attorney for Applicant

STATEMENT IN COMPLIANCE WITH 37 CFR § 1.821(f)


BOX PATENT APPLICATION
TO THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

In compliance with 37 CFR §1.821(f), the undersigned declares that the nucleotide and amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing."

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By 

Paula A. DeGrandis
Registration No. 43,581

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

66407 " 2 E 8460

SEQUENCE LISTING

<110> Ream, Walt et al.,
 <120> Plants Having Enhanced Gall Resistance and
 Methods and Compositions for Producing the Same
 <130> 53629
 <140>
 <141>
 <150> 60/107,185
 <151> 1998-11-05
 <160> 12
 <170> PatentIn Ver. 2.0
 <210> 1
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PCR Primer
 <400> 1
 cgggatccat gtcatagaacc tctccttgat aac 33
 <210> 2
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PCR Primer
 <400> 2
 cgggatcctg cgactcata 19
 <210> 3
 <211> 37
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PCR Primer
 <400> 3
 gaagatctga tcatggactg aatctaattt tcggtcc 37
 <210> 4
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PCR Primer
 <400> 4

gaagatctga tcactaataac attccgaacg g

31

<210> 5

<211> 747

<212> DNA

<213> *Agrobacterium tumefaciens*

<400> 5

```
gaagatctga tcatggactg aatctaattt tcgggtccaac ttgcacagga aagacgacga 60
ccgcgatagc tcttgcccag cagacagggc ttccagtcct ttcgcttgat cgggtccaat 120
gctgtcctca actatcaacc ggaagcggac gaccaacagt ggaagaactg aaaggaacga 180
cgctctctca cttgatgat cggcctctgg tggagggtat catcgcagcc aagcaagctc 240
atcataggct gatcgaggag gtgtataatc atgaggccaa cggcgggctt attcttgagg 300
gaggatccac ctggttgctc aactgcatgg cgcgaaacag ctattggagt gcagattttc 360
gttggcatat tattcgccac aagttaccog accaagagac cttcatgaaa gcggccaagg 420
ccagagttaa gcagatgttg caccocgctg caggccattc tattattcaa gagttggttt 480
atctttggaa tgaacctcgg ctgaggccca ttctgaaaga gatcgatgga tatcgatatg 540
ccatgttggt tgctagccag aaccagatca cggcagatat gctattgcag cttgacgcaa 600
atatggaagg taagttgatt aatgggatcg ctacaggagta tttcatccat gcgcgccaac 660
aggaacagaa attcccccac gttaacgcag ccgctttcga cggattcgaa ggtcatccgt 720
tcggaatgta ttagtgatca gatcttc 747
```

<210> 6

<211> 2

<212> PRT

<213> *Agrobacterium tumefaciens*

<400> 6

Met Asp

1

<210> 7

<211> 1807

<212> DNA

<213> *Agrobacterium tumefaciens*

<400> 7

```
cgggatccat gtcataaacc tctccttgat aaccagtgcg atcatctccc aacaaaaatg 60
gtggatctga caatgggtcga taaggcggat gaattggacc gcagggtttc cgatgccttc 120
ttagaacgag aagcttctag gggaaggagg attactcaaa gctccaccga gtgcagcgct 180
gggttagctt gcaaaaggct ggccgatggt cgcttccccg agatctcagc tgggtggaaag 240
gtagcagttc tctccgctta tatctatatt ggcaaagaaa ttctggggcg gatacttgaa 300
tcgaaacctt gggcgcgggc aacagtgagt ggtctcgttg ccatcgactt ggacaccatt 360
tgcattggatt tctccgaagc acaactaatc caagccctgt ttttgetgag cggtaaaaaga 420
tgtgcaccga ttgatcttag tcatctcgtg gccatttcaa tctctaagac tgccggcttt 480
cgaaccttgc caatgccgct gtacgagaat ggcacgatga aatgcgttac cgggtttacc 540
ataaccttgc aaggggcgct gccatttgac atggtagctt atggtcgaaa cctgatgctg 600
aagggttcgg caggttcctt tccaacaatc gacttgctct acgactgcag accgtttttt 660
gaccaatggt ccgatagtggt acggatcggc ttctttccgg aggatgttcc taagccgaaa 720
gtggcggtca ttggcgctgg catttccgga ctctgtggtg caaacgaact gcttcatgct 780
ggggtagacg atgttacaat atatgaagca agtgatcgtg ttggaggcaa gctttggtca 840
catgctttca gggacgctcc tagtgctcgt gccgaaatgg gggcgatgcg atttctcct 900
gctgcattct gcttggtttt ctctctcgag cgttacggcc tgtcttcgat gaggcggttc 960
ccaaatcccc gcacagtoga cacttaactg gtctaccaag gcgtccaata catgtggaaa 1020
gccgggcagc tgccaccgaa gctgttccat cgcgtttaca acggttggcg tgcgttcttg 1080
aaggacggtt ttcattgagc agatattgtg ttggcttcgc ctgtcgctat tactcaggcc 1140
ttgaaatcag gacacattag gtgggctcat gactcctggc aaatttggtc gaaccgtttc 1200
gggagggagt ccttctcttc agggatagag aggatctttc tgggcacaca tcctcctggt 1260
ggtaaacatg gagttttcct catgattggg acctattcaa gctaattgga ataggatctg 1320
gcgggggttg gtccagtttt tgaaagcggg tttattgaga tcctccgctt ggtcatcaac 1380
```

```

ggatatgaag aaaatcagcg gatgtgccct gaaggaatct cagaacttcc acgtcggatc 1440
gcatctgaag tgggttaacgg tgtgtctgtg agccagcgca tatgccatgt tcaagtcagg 1500
gcgattcaga aggaaaagac aaaaataaaag ataaggctta agagcgggat atctgaactt 1560
tatgataagg tgggtggtcac atctggactc gcaaatatcc aactcaggca ttgcctgaca 1620
tgcgatacca atattttttca ggcaccagtg aaccaagcgg ttgataacag ccatatgaca 1680
ggatcgtaaa aactcttccct gatgactgaa cgaaaattct ggtagacca tatcctcccg 1740
tcttgtgtcc tcatggacgg gatcgcaaaa gcagtgtatt gcctggacta tgagtcgcag 1800
gatcccg

```

```

<210> 8
<211> 2
<212> PRT
<213> Agrobacterium tumefaciens

```

```

<400> 8
Met Ser
1

```

```

<210> 9
<211> 2544
<212> DNA
<213> Agrobacterium tumefaciens

```

```

<400> 9
gaagatctga tcatggactg aatctaattt tcggtccaac ttgcacagga aagacgacga 60
ccgcgatagc tottgcccag cagacagggc ttccagtcct ttcgcttgat cgggtccaat 120
gctgtcctca actatcaacc ggaagcggac gaccaacagt ggaagaactg aaaggaacga 180
cgcgctctca ccttgatgat cggcctctgg tggaggggat catcgagcc aagcaagctc 240
atcataggct gatcgaggag gtgtataatc atgaggccaa cggcgggctt attcttgagg 300
gaggatccat gtcatgaacc tctccttgat aaccagtgcg atcatctccc aacaaaaatg 360
gtggatctga caatggtcga taaggcggat gaattggacc gcagggtttc cgatgccttc 420
ttagaacgag aagcttctag gggaaggagg attactcaaa gctccaccga gtgcagcgct 480
gggtagactt gcaaaaggct ggccgatggt cgcttccccg agatctcagc tgggtgaaag 540
gtagcagttc tctccgctta tatctatatt ggcaaaagaa ttctggggcg gatacttgaa 600
tcgaaacctt gggcgcgggc aacagtgaat ggtctcgttg ccatcgactt ggacaccatt 660
tgcattgatt tctccgaagc acaactaatc caagccctgt ttttgctgag cggtaaaaga 720
tgtgcaccga ttgatcttag tcatttctgt gccatttcaa tctctaagac tgccggcttt 780
cgaaccctgc caatgccgt gtacgagaat ggacagatga aatgcgttac cgggtttacc 840
ataacccttg aagggggcgt gccatttgac atggtagctt atggtcgaaa cctgatgctg 900
aagggttcgg caggttccct tccaacaatc gacttgctct acgactgcag accgtttttt 960
gaccaatgtt ccgatagtgg acggatcggc ttctttccgg aggatgttcc taagccgaaa 1020
gtggcggctc ttggcgctgg catttccgga ctctggtgg caaacgaact gcttcatgct 1080
gggtagacg atgttacaat atatgaagca agtgatcgtg ttggaggcaa gctttggtca 1140
catgctttca gggacgctcc tagtgtctgt gccgaaatgg gggcgatgcg atttctctct 1200
gctgcattct gcttgttttt ctctctcgag cgttacggcc tgtcttcgat gaggccgttc 1260
ccaaatcccg gcacagtcga cacttaactg gtctaccaag gcgtccaata catgtgaaa 1320
gccgggcagc tgccaccgaa gctgttccat cgcgtttaca acggttggcg tgcgttcttg 1380
aaggacggtt ttcatgagcg agatattgtg ttggttccgc ctgtcgctat tactcaggcc 1440
ttgaaatcag gacacattag gtgggctcat gactcctggc aaatttggct gaaccgtttc 1500
gggagggagt ccttctcttc agggatagag aggatctttc tgggcacaca tctcctggt 1560
ggtaaacatg gagttttcct catgattggg acctattcaa gctaattgga ataggatctg 1620
gcggggtttg gtccagtttt tgaaagcggg tttattgaga tcctccgctt ggtcatcaac 1680
ggatatgaag aaaatcagcg gatgtgccct gaaggaatct cagaacttcc acgtcggatc 1740
gcatctgaag tgggttaacgg tgtgtctgtg agccagcgca tatgccatgt tcaagtcagg 1800
gcgattcaga aggaaaagac aaaaataaaag ataaggctta agagcgggat atctgaactt 1860
tatgataagg tgggtggtcac atctggactc gcaaatatcc aactcaggca ttgcctgaca 1920
tgcgatacca atattttttca ggcaccagtg aaccaagcgg ttgataacag ccatatgaca 1980
ggatcgtaaa aactcttccct gatgactgaa cgaaaattct ggtagacca tatcctcccg 2040
tcttgtgtcc tcatggacgg gatcgcaaaa gcagtgtatt gcctggacta tgagtcgcag 2100
gatccacctc gttgctcaac tgcattggcg gaaacagcta ttggagtga gattttcgtt 2160

```

```

ggcatattat tcgccacaag ttacccgacc aagagacctt catgaaagcg gccaaaggcca 2220
gagttaagca gatgttgac cccgctgcag gccattctat tattcaagag ttggtttatc 2280
tttggaaatga acctcggctg aggcccattc tgaaagagat cgatggatat cgatatgcca 2340
tggtgtttgc tagccagaac cagatcacgg cagatatgct attgcagctt gacgcaaata 2400
tggaaggtaa gttgattaat gggatcgctc aggagtattt catccatgcg cgccaacagg 2460
aacagaaatt cccccaagtt aacgcagccg ctttcgacgg attcgaaggt catccgttcg 2520
gaatgtatta gtgatcagat cttc                                     2544

```

```

<210> 10
<211> 2268
<212> DNA
<213> Agrobacterium tumefaciens

```

```

<400> 10
atgtcagctt cacctctcct tgataaccag tgcgatcatc tcccaaccaa aatggtggat 60
ctgacaatgg tcgataaggc ggatgaattg gaccgcaggg tttccgatgc cttcttagaa 120
cgagaagctt ctaggggaag gaggattact caaagctcca ccgagtgcag cgctgggtta 180
gcttgcaaaa ggctggccga tggctcgctt cccgagatct cagctgggtg aaaggttagca 240
gttctctccg cttatatcta tattggcaaa gaaattcttg ggccgatact tgaatcgaaa 300
ccttgggcgc gggcaacagt gagtggcttc gttgccatcg acttggacac catttgcattg 360
gatttctccg aagcacaact aatccaagcc ctgtttttgc tgagcggtaa aagatgtgca 420
ccgattgatc ttagtcattt cgtggccatt tcaatctcta agactgccgg ctttcgaacc 480
ctgccaatgc cgctgtacga gaatggcagc atgaaatgcg ttaccgggtt taccataacc 540
cttgaagggg ccgtgccatt tgacatggta gcttatggtc gaaacctgat gctgaagggt 600
tcggcaggtt cttttccaac aatcgacttg ctctacgact gcagaccgtt ttttgaccaa 660
tgttccgata gtggacggat cggctctctt ccggaggatg ttcctaagcc gaaagtggcg 720
gtcattggcg ctggcatttc cggactcgtg gtggcaaacg aactgcttca tgctggggta 780
gacgatgtta caatatatga agcaagtgat cgtgttggag gcaagctttg gtcacatgct 840
ttcagggacg ctccatagtg cgtggccgaa atggggggcg tgcgatttcc tctgctgca 900
ttctgcttgt ttttcttctt cgagcgttac ggctgtctt cgatgaggcc gttcccaaat 960
cccgccacag tcgacactta cttggtctac caaggcgtcc aatacatgtg gaaagccggg 1020
cagctgccac cgaagctgtt ccacgcggtt tacaacgggt ggctgctgtt cttgaaggac 1080
ggttttcatg agcgagatat tgtgttggct tcgctgtcg ctattactca ggcttgaaa 1140
tcaggacaca ttaggtgggc tcatgactcc tggcaaat tggctgaaccg tttcgggagg 1200
gagtccttct cttcagggat agagaggatc tttctgggca cacatcctcc tgggtgtaaa 1260
catggagttt tctcatgat tgggacctat tcaagctaag gggaatagga tctggcgggg 1320
tttgggtccag tttttgaaag cgggtttatt gagatcctcc gcttgggtcat caacggatat 1380
gaagaaaatc agcggatgtg ccctgaagga atctcagaac ttccacgtcg gatcgcatct 1440
gaagtgggta acggtgtgtc tgtgagccag cgcataatgc atgttcaagt cagggcgatt 1500
cagaaggaaa agacaaaaat aaagataagg cttaagagcg ggatatctga actttatgat 1560
aaggtgggtg tcacatctgg actcgcaaat atccaactca ggcatgtgct gacatgcat 1620
accaatattt ttcaggcacc agtgaaccaa gcggttgata acagccatat gacaggatcg 1680
tcaaaactct tctgatgac tgaacgaaaa ttctggttag accatatct cccgtcttgt 1740
gtcctcatgg acgggatcgc aaaagcagtg tattgcttg actatgagtc gcaggatccg 1800
aatggtaaa gttctagtgt catcagttat acatgggagg acgactccca caagctgttg 1860
gcggtccccg acaaaaaaga gcgattatgt ctgctgcggg acgcaatttc gagatctttc 1920
ccggcggttg cccagcacct atttctgccc tgcgctgatt acgacaaaaa tgttattcaa 1980
catgattggc ttacagacga gaatgccggg ggagctttca aactcaacog gcgtgggtgag 2040
gatttttatt ctgaagaact tttctttcaa gcaactggaca cggctaata taccggagtt 2100
tacttggcgg gttgcagttg ttccttcaca ggtggatggg tggagggtgc tattcagacc 2160
gcgtgtaacg ccgtctgtgc aattatccac aattgtggag gcattttggc aaagggaat 2220
cctctcgaac actcttgga gagatataac taccgcagta gaaattag                                     2268

```

```

<210> 11
<211> 1404
<212> DNA
<213> Agrobacterium tumefaciens

```

```

<400> 11
atggtggcca ttacctcgtt agcccaaagc ctagaacacc tgaacggaa agactactcc 60
tgcttagaac tagtagaaac tctgatagcg cgttgtgaag ctgcaaaatc attaaacgcc 120

```

```

cttctggcta cagactggga tggtttgcg cgaagcgcca aaaaaattga tcgccatgga 180
aacgcgggag taggtctttg cggcattcca ctctgtttta aggcgaacat cgctaccggc 240
gtatttccca caagcgccgc tacgccggcg ctgataaacc acttgccaaa gataccatcc 300
cgcgtcgag aaagactttt ttcagctgga gcactgccgg gtgcctcggg aaatatgcat 360
gagttatcgt ttggaattac aagcaacaac tatgccaccg gggcggtgcg aaaccogtgg 420
aatccagatc tgataccagg gggctcaagc ggtggtgtgg ctgctgcggt agcaagccga 480
ttgatgttag gcggcatagg caccgatacc ggtgcatctg ttcgcctacc cgcagccctg 540
tgtggcgtag taggatttgc accgacgctt ggtagatata cgggagatcg gataataaccg 600
gttagcccta cccgggacac tcccggaaac atagcgcagt gcgtagccga tgttgtaatac 660
ctcgaccgga taatttcogg cacaccggag agaataccac ccgtgccgct gaaggggcta 720
aggatcgggc tccctacaac ctacttttat gatgaccttg atgctgatgt ggccctagca 780
gctgaaacaa cgattcgctt gctagcaaac aaaggcgtaa cttttgttga agctaaccatt 840
ccccaacttg acgaactgaa taaagggggc agcttcccag ttgcactcta tgaatttcca 900
cacgctctaa aacagtatct cgacgacttt gtaaaaaactg tttctttttc tgacgtcatc 960
aaaggaattc gtagccctga tgtagccaac attgccaatg cgcaaattga tggacatcaa 1020
atttccaaaag ctgaatatga actggccgcg cactccttca gaccaagact tcaagccacc 1080
tatcgcaact acttcaaact gaatagatta gatgctattc tcttcccaac agcacccttg 1140
gtggccagac ccatagggtca ggattcctca gttatccaca atggcacgat gctggacaca 1200
ttcaagatct acgtgcgaaa tgtggaccca agcagcaacg caggcctacc tggcttgagc 1260
attcctgttt gcctgacacc tgatcgcttg cctgttgtaa tggagatcga tggattagcg 1320
gattcagacc aacgtctgtt agcaatcggg ggggcatttg aagaagccat tggattccga 1380
tattttgccg gtttacccaa ttaa 1400

```

<210> 12
<211> 723
<212> DNA
<213> Agrobacterium tumefaciens

```

<400> 12
atggacctgc atctaatttt cgggtccaact tgcacaggaa agacgacgac cgcgatagct 60
cttgcccagc agacagggct tccagtcctt tcgcttgatc ggggtccaatg ctgtcctcaa 120
ctatcaaccg gaagcggacg accaacagtg gaagaactga aaggaacgac gcgtctctac 180
cttgatgata ggctctggtt ggaggggtatc atcgacagcca agcaagctca tcataggctg 240
atcgaggagg tgtataatca tgaggccaac ggcgggctta ttcttgaggg aggatccacc 300
tcgttgctca actgcatggc gcgaaacagc tattggagtg cagattttcg ttggcatatt 360
attcgccaca agttaccgga ccaagagacc ttcattgaaag cggccaaggc cagagttaag 420
cagatgttgc accccgctgc aggccattct attattcaag agttggttta tctttggaat 480
gaacctcggc tgaggcccat tctgaaagag atcgatggat atcgatatgc catgttggtt 540
gctagccaga accagatcac ggcatatg ctattgcagc ttgacgcaaa tatggaagg 600
aagttgatta atgggatcgc tcaggagtat ttcattccatg cgcgccaaca ggaacagaaa 660
ttccccaag ttaacgcagc cgctttcgac ggattcgaag gtcattccgtt cggaatgtat 720
tag 723

```